SEC Comment Letter 0000000000-23-012547 to Evoke Pharma Inc (EVOK) (CIK 0001403708)
Evoke Pharma Inc (EVOK) (CIK 0001403708)
Date: Nov. 15, 2023 · CIK: 0001403708 · Accession: 0000000000-23-012547
AI Filing Summary & Sentiment
File numbers found in text: 333-275443
Letter
United States securities and exchange commission logo November 15, 2023 David A. Gonyer, R.Ph. Chief Executive Officer and Director Evoke Pharma, Inc. 420 Stevens Avenue, Suite 230 Solana Beach, CA 92075 Re:Evoke Pharma, Inc. Registration Statement on Form S-1 Filed November 9, 2023 File No. 333-275443 Dear David A. Gonyer: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tim Buchmiller at 202-551-3635 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Anthony Gostanian, Esq.
Show Raw Text
United States securities and exchange commission logo
November 15, 2023
David A. Gonyer, R.Ph.
Chief Executive Officer and Director
Evoke Pharma, Inc.
420 Stevens Avenue, Suite 230
Solana Beach, CA 92075
Re:Evoke Pharma, Inc.
Registration Statement on Form S-1
Filed November 9, 2023
File No. 333-275443
Dear David A. Gonyer:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tim Buchmiller at 202-551-3635 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Anthony Gostanian, Esq.